Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE
NCT05206812Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Sep 2022
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoint: Major pathologic response. Started Sep 2022; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05206812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05206812.